Home ›
Lymphoma Trials ›
NCT06158399
AZA Combined With RCHOP in P53-mutated DLBCL.
To evaluate the efficacy and adverse effects of Azacitidine in combination with R-CHOP (ARCHOP) for the treatment of TP53-mutated previously untreated Diffuse large B-cell lymphoma
Trial Details
NCT ID NCT06158399
Phase PHASE2
Sponsor The First Affiliated Hospital of Xiamen University
Status RECRUITING
Cancer Type Lymphoma
Interventions Azacitidine in combination with R-CHOP
Locations (sample) Xiamen, Fujian, China|24.47979,118.08187
Key Eligibility Criteria
(1)18-70 years old; 2) New-onset TP53 mutant DLBCL; 3) ECOG 0-2; 4) LVEF \>45%; 5) HBV-positive serology (occult carriers: anti-HBeAg +, HbsAg-, an…
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lymphoma Trials on Trialify →